LANTERN PHARMA INC (LTRN) Stock Income Statement
NASDAQ:LTRN - Nasdaq - US51654W1018 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 21.26M | 22.22M | 17.88M | 14.43M | 12.59M | |||
| Research and Development | 15.14M | 16.13M | 11.89M | 8.60M | 7.57M | |||
| Selling, General, and Administrative Expenses | 6.12M | 6.09M | 5.98M | 5.83M | 5.02M | |||
| Operating Income | -21.26M | -22.22M | -17.88M | -14.43M | -12.59M | |||
| Interest Income/Expense | 691.30K | 742.40K | 765.40K | 200.00K | 120.00K | |||
| Other Income/Expense | 690.10K | 692.90K | 1.15M | -30.00K | N/A | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | 110.00K | |||
| Income Before Taxes | -19.88M | -20.78M | -15.96M | -14.26M | -12.36M | |||
| Net Income | -19.88M | -20.78M | -15.96M | -14.26M | -12.36M | |||
| EBITDA | -21.24M | -22.20M | -17.86M | -14.42M | -12.58M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.85 | -1.93 | -1.47 | -1.31 | -1.13 | |||
| Non GAAP EPS | -1.84 | -1.93 | -1.48 | -1.31 | -1.13 | |||
| Statistics | ||||||||
All data in USD